[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586941":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":188,"collaborators":19,"id":190,"slug":191,"hasResults":192,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":19,"eligibilityCriteria":196,"healthyVolunteers":192,"sex":197,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":19,"studyType":203,"phases":204,"briefSummary":207,"conditions":208,"keywords":213,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":225},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"AZD4360 Monotherapy","EXPERIMENTAL",[12],"Drug: AZD4360",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","AZD4360","Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2)",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[27,41,50,59,69,77,85,93,104,112,120,130,138,146,154,164,172,180],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":19},"Research Site","RECRUITING","Santa Monica","California","90404","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-118.49138,34.01949,{"lat":39,"lon":38},{"facility":28,"status":29,"city":42,"state":43,"zip":44,"country":33,"countryCode":34,"cosmosGeoPoint":45,"geoPoint":49,"contacts":19},"Providence","Rhode Island","02903",{"type":36,"coordinates":46},[47,48],-71.41283,41.82399,{"lat":48,"lon":47},{"facility":28,"status":29,"city":51,"state":52,"zip":53,"country":33,"countryCode":34,"cosmosGeoPoint":54,"geoPoint":58,"contacts":19},"Houston","Texas","77030",{"type":36,"coordinates":55},[56,57],-95.36327,29.76328,{"lat":57,"lon":56},{"facility":28,"status":29,"city":60,"state":19,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":68,"contacts":19},"Beijing","100730","China","CN",{"type":36,"coordinates":65},[66,67],116.39723,39.9075,{"lat":67,"lon":66},{"facility":28,"status":29,"city":70,"state":19,"zip":71,"country":62,"countryCode":63,"cosmosGeoPoint":72,"geoPoint":76,"contacts":19},"Chengdu","610041",{"type":36,"coordinates":73},[74,75],104.06667,30.66667,{"lat":75,"lon":74},{"facility":28,"status":29,"city":78,"state":19,"zip":79,"country":62,"countryCode":63,"cosmosGeoPoint":80,"geoPoint":84,"contacts":19},"Shanghai","201318",{"type":36,"coordinates":81},[82,83],121.45806,31.22222,{"lat":83,"lon":82},{"facility":28,"status":29,"city":86,"state":19,"zip":87,"country":62,"countryCode":63,"cosmosGeoPoint":88,"geoPoint":92,"contacts":19},"Wuhan","430040",{"type":36,"coordinates":89},[90,91],114.26667,30.58333,{"lat":91,"lon":90},{"facility":28,"status":94,"city":95,"state":19,"zip":96,"country":97,"countryCode":98,"cosmosGeoPoint":99,"geoPoint":103,"contacts":19},"NOT_YET_RECRUITING","Berlin","12200","Germany","DE",{"type":36,"coordinates":100},[101,102],13.41053,52.52437,{"lat":102,"lon":101},{"facility":28,"status":29,"city":105,"state":19,"zip":106,"country":97,"countryCode":98,"cosmosGeoPoint":107,"geoPoint":111,"contacts":19},"Dresden","01307",{"type":36,"coordinates":108},[109,110],13.73832,51.05089,{"lat":110,"lon":109},{"facility":28,"status":29,"city":113,"state":19,"zip":114,"country":97,"countryCode":98,"cosmosGeoPoint":115,"geoPoint":119,"contacts":19},"Frankfurt","60488",{"type":36,"coordinates":116},[117,118],10.53333,49.68333,{"lat":118,"lon":117},{"facility":28,"status":29,"city":121,"state":19,"zip":122,"country":123,"countryCode":124,"cosmosGeoPoint":125,"geoPoint":129,"contacts":19},"Chūōku","104-0045","Japan","JP",{"type":36,"coordinates":126},[127,128],130.67068,33.63867,{"lat":128,"lon":127},{"facility":28,"status":29,"city":131,"state":19,"zip":132,"country":123,"countryCode":124,"cosmosGeoPoint":133,"geoPoint":137,"contacts":19},"Kashiwa","227-8577",{"type":36,"coordinates":134},[135,136],139.97732,35.86224,{"lat":136,"lon":135},{"facility":28,"status":29,"city":139,"state":19,"zip":140,"country":123,"countryCode":124,"cosmosGeoPoint":141,"geoPoint":145,"contacts":19},"Kōtoku","135-8550",{"type":36,"coordinates":142},[143,144],143.14297,42.50417,{"lat":144,"lon":143},{"facility":28,"status":94,"city":147,"state":19,"zip":148,"country":123,"countryCode":124,"cosmosGeoPoint":149,"geoPoint":153,"contacts":19},"Sendai","980-8574",{"type":36,"coordinates":150},[151,152],140.86667,38.26667,{"lat":152,"lon":151},{"facility":28,"status":29,"city":155,"state":19,"zip":156,"country":157,"countryCode":158,"cosmosGeoPoint":159,"geoPoint":163,"contacts":19},"Glasgow","G12 0YN","United Kingdom","UK",{"type":36,"coordinates":160},[161,162],-4.25763,55.86515,{"lat":162,"lon":161},{"facility":28,"status":94,"city":165,"state":19,"zip":166,"country":157,"countryCode":158,"cosmosGeoPoint":167,"geoPoint":171,"contacts":19},"Leeds","LS9 7TF",{"type":36,"coordinates":168},[169,170],-1.54785,53.79648,{"lat":170,"lon":169},{"facility":28,"status":29,"city":173,"state":19,"zip":174,"country":157,"countryCode":158,"cosmosGeoPoint":175,"geoPoint":179,"contacts":19},"London","EC1A 7BE",{"type":36,"coordinates":176},[177,178],-0.12574,51.50853,{"lat":178,"lon":177},{"facility":28,"status":94,"city":181,"state":19,"zip":182,"country":157,"countryCode":158,"cosmosGeoPoint":183,"geoPoint":187,"contacts":19},"Oxford","OX3 7LE",{"type":36,"coordinates":184},[185,186],-1.25596,51.75222,{"lat":186,"lon":185},{"type":189,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100586941","phase-1-study-for-azd4360-in-participants-with-advanced-solid-tumours-100586941",false,"NCT06921928","Study for AZD4360 in Participants With Advanced Solid Tumours","A Phase I\u002FII Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours","Inclusion Criteria:\n\n1. Participant must be ≥ 18 at the time of signing the ICF.\n2. Eastern cooperative oncology group performance status of 0-1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.\n3. Minimum life expectancy of 12 weeks in the opinion of the Investigator.\n\n4 Adequate organ and marrow function, as defined by protocol.\n\n5\\. Contraceptive use by men or women should be consistent with local regulations, as defined by protocol.\n\n6\\. Histologically confirmed advanced or metastatic Pancreatic ductal adenocarcinoma (PDAC), Gastric or Gastroesophageal junction cancer (G\u002FGEJC), and Biliary tract cancer (BTC) with documented positive CLDN18.2 expression.\n\n7\\. Participants must have received at least one prior line of systemic therapy in the advanced\u002Fmetastatic disease.\n\n8\\. At least one measurable lesion according to RECIST v1.1.\n\nExclusion Criteria:\n\n1. Human Epidermal Growth Factor Receptor 2 (HER2) positive (3+ by IHC or 2+ by IHC and positive by in situ hybridisation) or indeterminate G\u002FGEJC participants.\n2. Unstable or active peptic ulcer disease or digestive tract bleeding including but not limited to clinically significant bleeding in the setting of prior CLDN18.2 directed therapy.\n3. Participants with clinically significant ascites that require drainage.\n4. Central nervous system (CNS) metastases or CNS pathology, as defined by protocol.\n5. With spinal cord compression or with high risk of paralysis.\n6. History of non-infectious interstitial lung disease\u002Fpneumonitis.\n7. Participant has cardiac abnormalities, as defined by protocol.\n8. History of another primary malignancy within 2 years prior to screening.\n9. Known serologic status reflecting active hepatitis B or hepatitis C.\n10. Known HIV infection that is not well controlled.\n11. Active tuberculosis infection.","ALL","18 Years","130 Years",{"count":201,"type":202},117,"ESTIMATED","INTERVENTIONAL",[205,206],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.",[209,210,211,212],"Gastric Cancer","Gastroesophageal Junction Cancer","Biliary Tract Cancer","Pancreatic Ductal Adenocarcinoma",[209,210,211,212,214,16,215],"Advanced Solid Tumours","Claudin 18.2","2026-06-15",{"date":218,"type":219},"2026-06-16","ACTUAL",{"date":221,"type":219},"2025-04-29",{"date":223,"type":202},"2027-12-16",{"name":5,"class":6},18]